Silexion Therapeutics (NASDAQ: SLXN) posts positive SIL204 pan-KRAS data

Rhea-AI Filing Summary

Silexion Therapeutics Corp filed a current report to share new preclinical research results for its drug candidate SIL204. On September 30, 2025, the company issued a press release titled “Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer.”

The report states that new human cell line data confirm pan-KRAS activity for SIL204, with inhibition reported as high as 99.7%, and describes first evidence related to gastric cancer. The press release is furnished as Exhibit 99.1, and this information is provided under Regulation FD as “furnished,” not “filed,” which limits its use in certain legal contexts.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000202241600-0000000972NASDAQNASDAQ00020224162025-09-302025-09-300002022416slxn:OrdinarySharesParValue00135PerShareMember2025-09-302025-09-300002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf155250PerShareMember2025-09-302025-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 30, 2025

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands		001-42253		N/A
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

12 Abba Hillel Road Ramat-Gan, Israel		5250606
(Address of principal executive offices)		(Zip Code)

+972-3-756-4999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0135 per share		SLXN		The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share		SLXNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 30, 2025, Silexion Therapeutics Corp issued a press release entitled “Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer” A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits 

(d) Exhibits

99.1		Press Release dated September 30, 2025
104		Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILEXION THERAPEUTICS CORP
Date: September 30, 2025	/s/ Ilan Hadar
	Name:	Ilan Hadar
	Title:	Chief Executive Officer

FAQ

What did Silexion Therapeutics Corp (SLXN) disclose in this 8-K?

Silexion Therapeutics Corp reported that it issued a press release on September 30, 2025, describing positive new human cell line data for its drug candidate SIL204.

What new data about SIL204 did Silexion Therapeutics highlight for SLXN?

The company highlighted positive human cell line data confirming pan-KRAS activity of SIL204, reporting up to 99.7% inhibition and first evidence in gastric cancer, as stated in the press release title.

How is the SIL204 information treated for securities law purposes in this SLXN filing?

The company states that the information in Item 7.01, including the press release, is “furnished” and not “filed” under the Exchange Act and is not incorporated by reference into Securities Act filings.

Which exhibit did Silexion Therapeutics attach with the SIL204 data update?

Silexion attached Exhibit 99.1, described as a Press Release dated September 30, 2025, along with Exhibit 104 for the cover page Inline XBRL data file.

Who signed the Silexion Therapeutics (SLXN) 8-K related to SIL204?

The report was signed on behalf of Silexion Therapeutics Corp by Ilan Hadar, who is identified as the company’s Chief Executive Officer.

On which exchange are Silexion Therapeutics’ ordinary shares and warrants listed?

The filing states that Silexion’s ordinary shares (symbol SLXN) and warrants exercisable for ordinary shares (symbol SLXNW) are listed on The Nasdaq Stock Market LLC.